Portfolio company Arclin is in the process of buying DuPont’s Aramids business in a transaction valuing it at approximately $1.8 billion.

Arclin has received fully committed financing in connection with the transaction, which is expected to close in the first quarter of 2026, subject to customary regulatory approval.

At close, DuPont will receive pre-tax cash proceeds of approximately $1.2 billion, subject to customary transaction adjustments, a note receivable of $300 million, and a non-controlling common equity interest in the future Arclin company currently valued at $325 million, which is expected to represent an approximate 17.5% stake.

“The Aramids transaction further enhances the strategic focus of our portfolio, while also increasing the growth and margin profile,” said DuPont CEO Lori Koch. “The transaction is structured to maximise value for our shareholders by providing significant cash proceeds at close which will be re-deployed to further drive value creation, while also allowing DuPont shareholders to participate in Arclin’s growth potential through our retained equity interest.”

“The addition of Kevlar and Nomex to the Arclin portfolio presents a unique opportunity to transform our business with increased scale, broader global reach and market-leading application development capabilities,” added Arclin CEO Bradley Bolduc. “The growth potential this acquisition presents will allow us to double down on our commitment to bringing impactful solutions and products to market, such as Arclin Firepoint.”

With around 1,900 employees and five manufacturing sites, the Aramids business generated net sales of $1.3 billion in 2024.

Arclin is a leading materials science company and manufacturer of polymer technologies, engineered products and specialised materials. Headquartered in Alpharetta, Georgia, it has offices and manufacturing facilities throughout the USA, Canada and UK and manufactures worldwide.

www.arclin.com